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Vertebrate species possess two retinal guanylate cyclases (retGC1 and retGC2) and at
least two guanylate cyclase activating proteins (GCAPs), GCAP1 and GCAP2. GCAPs
function as Ca2+ sensors that regulate the activity of guanylate cyclases. Together, these
proteins regulate cGMP and Ca2+ levels within the outer segments of rod and cone
photoreceptors. Mutations in GUCY2D, the gene that encodes retGC1, are a leading
cause of the most severe form of early onset retinal dystrophy, Leber congenital amaurosis
(LCA1).Thesemutations, which reduce or abolish the ability of retGC1 to replenish cGMP in
photoreceptors, are thought to lead to the biochemical equivalent of chronic light exposure
in these cells. In spite of this, the majority of LCA1 patients retain normal photoreceptor
laminar architecture aside from foveal cone outer segment abnormalities, suggesting they
may be good candidates for gene replacement therapy. Work began in the 1980s to
characterize multiple animal models of retGC1 deﬁciency. 34 years later, all models have
been used in proof of concept gene replacement studies toward the goal of developing a
therapy to treat GUCY2D-LCA1. Here we use the results of these studies as well as those
of recent clinical studies to address speciﬁc questions relating to clinical application of a
gene therapy for treatment of LCA1.
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INTRODUCTION
The ability to process light into an electrochemical signal depends
on the precise regulation of levels of cGMP and Ca2+ within
the outer segments of rod and cone photoreceptor cells. In
the absence of light stimulation, intracellular cGMP and Ca2+
levels are high and a continuous ﬂow of Na+ and Ca2+ ions
through cGMP-gated channels and Na+/Ca2+ exchangers keeps
the cell in a depolarized state. Activation of rhodopsin or cone
opsins in rod and cone outer segments, respectively, leads to
activation of transducin that in turn activates cGMP phospho-
diesterase (PDE) leading to a reduction in the concentration of
cGMP in the outer segment. Reduction of cGMP leads to closure
of cGMP-gated channels, reduced Na+/Ca2+ inﬂux and hyper-
polarization of the cell (Pugh et al., 1997). Recovery of light
stimulated photoreceptors to the dark state is hastened by the
decrease in intracellular Ca2+ that results from continued expul-
sion of Ca2+ by Na+/Ca2+-K+ exchangers. Calcium has several
roles in photoreceptor cells, one of which is to regulate the activ-
ity of retinal guanylate cyclases, retGC1 and retGC2 (Koch and
Stryer, 1988). It does so by binding to guanylate cyclase activat-
ing proteins (GCAPs), a family of calcium-binding proteins that
regulate the activity of retGCs (Polans et al., 1996). Two variants
of guanylate cyclases (retGC1 and retGC2) and at least two vari-
ants of GCAPs (GCAP1 and GCAP2) are present in the outer
segments of vertebrate photoreceptors (Shyjan et al., 1992; Mar-
gulis et al., 1993; Dizhoor et al., 1994; Goraczniak et al., 1994,
1997; Palczewski et al., 1994; Lowe et al., 1995; Yang et al., 1995;
Imanishi et al., 2004). In the dark, high levels of intracellular
Ca2+ promote its binding to GCAP and inhibit the ability of
this protein to activate retGCs. Reduction of free, intracellu-
lar Ca2+ following light stimulation leads to a decrease in the
amount of Ca2+ bound to GCAP in exchange for Mg2+, which
allows this protein to activate retGCs (Peshenko and Dizhoor,
2006; Figure 1). In vivo, retGC1 is the preferred target of
GCAP1 (Olshevskaya et al., 2012). In vitro, some studies show
that GCAP1 and GCAP2 can activate both retGCs, albeit with
slightly different afﬁnities and sensitivity to Ca2+ (Hwang et al.,
2003; Peshenko and Dizhoor, 2004; Peshenko et al., 2011) while
another shows that GCAP1 cannot activate retGC2 (Haeseleer
et al., 1999).
Mutations in GUCY2D, the gene that encodes retGC1, are
associated with the severe, early onset, autosomal recessive dis-
order Leber congenital amaurosis-1 (LCA1; Perrault et al., 1996,
2000). LCA1 causing mutations are found throughout GUCY2D,
can alter the enzyme’s structure or stability, affect transport of
other peripheral membrane associated protein, and are frequently
null (Karan et al., 2010; Jacobson et al., 2013). Without fully func-
tional retGC1 to replenish intracellular cGMP, as is the case in
LCA1, cGMP-gated cation channels will remain closed as they
are in the light stimulated state. Hence, mutations in GUCY2D
are thought to induce the biochemical equivalent of chronic
light exposure in photoreceptors. LCA1 patients routinely present
with severely reduced visual acuities, attenuated or extinguished
electroretinogram (ERG), nystagmus, digito-ocular signs, and
apparently normal fundus appearance (Perrault et al., 1999a, 2000;
Hanein et al., 2004; Yzer et al., 2006; den Hollander et al., 2008).
While early reports indicated retinal degeneration was associated
with this form of LCA (Milam et al., 2003; Porto et al., 2003),
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FIGURE 1 | The role of retinal guanylate cyclase (retGC) in
phototransduction. A photon of light activates rhodopsin initiating a cascade
of events, the end result of which is reduction of cGMP, closure of
cGMP-gated channels and reduction of intracellular Ca2+ in photoreceptor
outer segments. Continued expulsion of Ca2+ by Na+/Ca2+-K+ exchangers
(NCKX) results in activation of retGC by GCAP. retGC replenishes intracellular
cGMP which reopens cGMP-gated channels allowing for Ca2+ inﬂux and a
return of the photoreceptor to its dark-adapted state.
later studies revealed preservation of retinal laminar architecture
in LCA1 patients (Simonelli et al., 2007; Pasadhika et al., 2010;
Jacobson et al., 2013).
Preservation of retinal structure despite profound visual dis-
turbance suggests that LCA1 patients would be good candidates
for gene replacement therapy. Before initiating such clinical tri-
als there are major questions that need to be answered. Here we
stepwise address these questions by reviewing ﬁndings of proof
of concept studies utilizing different animal models of retGC1
deﬁciency (results summarized in Table 1). Additionally, we pro-
vide an update on efforts to clinically apply a gene therapy for
LCA1.
WILL GUCY2D GENE REPLACEMENT RESTORE RETINAL
FUNCTION IN VIVO?
The ﬁrst animal model used to investigate gene replacement for
retGC1was the retinal degeneration (rd) chicken, also referred to as
the GUCY1∗B chicken. This cone- dominant, avian model carries
a null, naturally occurring deletion/insertion mutation in the gene
encoding retGC1 (Semple-Rowland et al., 1998). As a consequence
of retGC1 deﬁciency, photoreceptors of post-hatch day 1 (P1)
GUCY1∗Bchickens have only 10–20%cGMPrelative to that found
in age-matched, wild type controls and affected chickens are blind
at hatch. They have unrecordable ERGs and lack optokinetic and
volitional visual behavior (Ulshafer et al., 1984; Williams et al.,
2006). These biochemical and visual disturbances occur prior to
photoreceptor loss which doesnot begin until 1 week post-hatch
(Cheng et al., 1980; Ulshafer et al., 1984) and proceeds in a central
to peripheral fashion with cones completely lost by 3.5 months
and rods lost by 8 months (Ulshafer and Allen, 1985a,b).
Due to the technical difﬁculty associated with performing
subretinal injections in chicken, an in ovo treatment paradigm
was developed. For its ability to stably transduce retinal pro-
genitor cells (Miyoshi et al., 1997), HIV-1-based lentivirus (LV)
was used to deliver a cDNA encoding bovine retGC1 under the
control of an elongation factor 1 alpha (EF1α) promoter to the
neural tube of developing GUCY1∗B embryos (Williams et al.,
2006). Bovine retGC1 (bGC1) was chosen for its veriﬁed activ-
ity in the presence of chicken GCAPs in vitro (Williams et al.,
2006). At 1 month post-hatch, ERG testing under both dark
and light-adapted conditions revealed that LV-EF1α-bGC1 treat-
ment produced modest increases in photoreceptor-mediated a-
wave amplitudes in treated chickens (∼6% of wild type). These
results were the ﬁrst demonstration that retGC1 gene replacement
could restore retinal function. ERG improvements were associated
with a restoration of visually guided behavior, as assessed by
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Table 1 | Summary of proof of concept experiments.
Animal
model
Vector Treatment
age
ERG results Behavior outcomes Structural
results
Length of
study
GUCY1*B
chicken
LV-EF1α-bGC1 E2 Cones/rods: up to 6% of
WT
Cone-mediated OKN
reﬂex/volitional behavior
Degeneration
slowed
5 weeks
GC1KO
mouse
AAV5-smCBA-Gucy2e P14–P25 Cones: up to ∼45% ofWT Cone-mediated OKN reﬂex Cone
preservation
3 months,
1 year
AAV5-hGRK1-Gucy2e P14–P25 Cones: up to ∼45% ofWT Cone-mediated OKN reﬂex Cone
preservation
3 months,
1 year
AAV8-hGRK1-GUCY2D P10 Cones: up to ∼65% ofWT Cone-mediated OKN reﬂex Cone
preservation
6 months
Rods: up to 100% ofWT
AAV8(Y733F)-hGRK1-
Gucy2e
P14–P25 Cones: up to ∼45% ofWT Cone-mediated OKN reﬂex Cone
preservation
1 year
GC1/GC2DKO
mouse
AAV8(Y733F)-hGRK1-
Gucy2e
P21–P108 Cones: up to ∼42% ofWT Cone-mediated OKN reﬂex Cone/rod
preservation
1 year
Rods: up to ∼44% ofWT Cone and rod-mediated
visual acuity
optokinetic reﬂex testing (Wallman andVelez, 1985) and volitional
visually guided behavior tests (Williams et al., 2006). In addition,
a slowing of retinal degeneration was observed (Williams et al.,
2006). Taken together, these results were exciting proof of concept
that gene replacement therapy could be effective for treatment
of LCA1. However, there were multiple limitations associated
with this study that needed to be overcome. First, the thera-
peutic effect was transient, with ERG and behavioral responses
disappearing after the latest time points analyzed (5 weeks post-
hatch) and retinal degeneration continuing unabated (Williams
et al., 2006; Verrier et al., 2011). Second, multiple facets of the
therapeutic strategy lacked clinical translatability- (1) Therapeu-
tic retGC1 was delivered embryonically, a currently untenable
task in patients and also requiring in-utero genotyping. (2) An
integrating, lentiviral vector was used. While proven effective for
transducing retinal precursors, LV has demonstrated little to no
ability to transduce post-mitotic photoreceptors (Miyoshi et al.,
1997; Bainbridge et al., 2001; Pang et al., 2006; Lipinski et al.,
2014). (3) Data was obtained in a non-mammalian model of
retGC1 deﬁciency. Together, this highlighted the need to test
therapy using more clinically relevant animal models and vector
platform.
WILL POST-NATALLY DELIVERED retGC1 RESTORE RETINAL
FUNCTION IN A MAMMALIAN MODEL OF retGC1
DEFICIENCY?
The ﬁrst mammalian model retGC1 deﬁciency to be described was
the guanylate cyclase-1 knockout (GC1KO) mouse (Yang et al.,
1999). Insertion of a neomycin resistance cassette in exon 5 of
Gucy2e (the murine homolog of GUCY2D) resulted in truncation
of retGC1, rendering it null (Yang et al., 1999). Cone-mediated
ERGs are unrecordable by 5 weeks but cones are not completely
degenerated in this mouse until ∼6 months of age (Yang et al.,
1999; Coleman et al., 2004). Rods, on the other hand, do not
degenerate and maintain variable levels of function (∼30–50% of
WT; Yang et al., 1999) which is owed to the presence of retGC2
in those cells (Baehr et al., 2007). GCAP1 and GCAP2 transcripts
and GCAP1 expression are down-regulated (Coleman et al., 2004)
and light-induced translocation of cone arrestin is disrupted as a
result of retGC1 deﬁciency in this model (Coleman and Semple-
Rowland, 2005). The temporal dissociation between loss of cone
function and structure in GC1KO mice, provides a window of
therapy for gene replacement.
For its safety proﬁle and proven ability to transduce post-
mitotic photoreceptors following subretinal injection of murine
retina (Yang et al., 2002), a serotype 5 adeno associated virus (AAV)
was chosen to deliver bovine retGC1 (the same cDNA delivered
to the GUCY1∗B chicken) under the control of either the ubiqui-
tous, smallCBA(smCBA)orphotoreceptor-speciﬁc,murine opsin
(MOPS) promoter to the GC1KO mouse (Haire et al., 2006). Post-
natal day 21 (P21) treatment with AAV5-bGC1 failed to improve
retinal function (ERG) in treated mice. However, AAV-mediated
retGC1 expression was restricted to photoreceptor outer segments
and restoration of light-induced cone arrestin translocation, a bio-
chemical correlate of functionality in these cells, was observed at
4 weeks post-treatment (Haire et al., 2006), suggesting that the
light signaling cascade in GC1KO cones had been at least partially
reset following treatment.
Investigators speculated that the species non-speciﬁc nature of
the delivered transgene may have dampened the therapeutic out-
come. Indeed, subretinal delivery of murine Gucy2e via an AAV5
vector containing either the ubiquitous smCBA or photoreceptor-
speciﬁc human rhodopsin kinase (hGRK1) promoter led to robust
improvements (∼45%ofWT) in cone-mediated ERGs (Boye et al.,
2010). These improvements were stable over the course of this ini-
tial study (at least 3 months post-treatment) and provided the
ﬁrst evidence that an AAV-based vector could restore retinal func-
tion to a mammalian model of retGC1 deﬁciency (Boye et al.,
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2010). Later studies would go on to show that stable restoration
of cone function (ERG) is achievable over the long term (Boye
et al., 2011; Mihelec et al., 2011). Subretinally delivered AAV8
containing the hGRK1 promoter and human GUCY2D cDNA sta-
bly restored cone function (∼65% of WT) for at least 6 months
(Mihelec et al., 2011). In the longest follow up reported to date,
subretinally delivered AAV5 or capsid mutant AAV8(Y733F) con-
taining either the smCBA or hGRK1 promoter and murine Gucy2e
cDNA stably restored cone function (∼45% of WT) for at least
1 year post-treatment (Boye et al., 2011). A notable difference
between these two studies was the level of cone function achieved
(65 vs. 45% of WT). Mihelec et al. (2011) subretinally deliv-
ered AAV-GUCY2D to GC1KO mice at P10 (an age prior to
natural eye opening) whereas Boye et al. (2011) delivered AAV-
Gucy2e between P14–P25. Earlier intervention was likely more
effective at combating the chronic effects of hyperpolarization
that GC1KO cones endure upon light stimulation. Regardless of
these differences, the robust and stable functional improvements
in cone function following AAV-retGC1 treatment (including
with a clinically relevant human cDNA) in GC1KO mice laid
the groundwork for development of an AAV-based treatment for
LCA1.
As a follow up to these studies, cone-mediated function was
also evaluated in the retGC1/retGC2 double knockout (GCDKO
mouse following subretinal delivery of AAV8(Y733F)-hGRK1-
Gucy2e (Boye et al., 2013). Treatment of thismodel, inwhich cones
and rods are functionally silent and progressively degenerate, also
resulted in stable and robust improvements in cone function for
at least 1 year post-treatment (Boye et al., 2013). As in all GC1KO
studies, AAV-mediated retGC1 expression was restricted to the
outer segments of rods and cones in treated GCDKO mice. The
GCDKO mouse and gene replacement experiments in this model
will be discussed in more detail below.
DOES RESTORATION OF CONE FUNCTION TRANSLATE INTO
USEFUL VISION?
Adenoassociated virus-mediated expressionof retGC1 inphotore-
ceptors of GC1KO mice effectively reset the phototransduction
cascade in cones, allowing them to send electrochemical signals
to downstream neurons which were detected via full ﬁeld ERG
electrodes (Boye et al., 2010, 2011; Mihelec et al., 2011). How-
ever, the existence of functional neural circuits within the retina
does not ensure that electrochemical signals are properly relayed
to higher order processing centers in the brain and experienced
as “vision.” Even if the biochemical defect within photorecep-
tors is corrected via restoration of retGC1, it is unclear what
role amblyopia (the inability of the retina to send visual infor-
mation to the brain) will play on the treatment outcome. To gain
insight into this question, multiple visually guided behavior tests
were used to further characterize therapy in AAV-treated GC1KO
mice.
Two tests, each of which evaluates the integrity of different
visual processing centers of the brain, were used to determine
whether useful cone vision could be restored to treated mice.
A virtual optokinetic system was used to evaluate the integrity
of subcortical retinal efferents (Douglas et al., 2005). While
untreated GC1KO mice lack cone-mediated behavior, signiﬁcant
improvements in cone-mediated spatial frequency thresholds and
contrast sensitivities were seen inGC1KOmice treatedwithAAV5-
hGRK1-Gucy2e, AAV5-smCBA-Gucy2e, AAV8(Y733F)-hGRK1-
Gucy2e or AAV8-hGRK1-GUCY2D (Boye et al., 2010, 2011; Mih-
elec et al., 2011) with behavior resembling that of normal, sighted
congenic mice. Improvements in cone-mediated behavior were
observed out to 4 months post-treatment (Mihelec et al., 2011),
the latest time point evaluated in this mouse model. Analy-
sis of cone-mediated behavior was also evaluated in GCDKO
mice via Morris Water Maze (under photopic conditions), a
test used to analyze cortically driven visual behavior (Boye et al.,
2013). AAV8(Y733F)-hGRK1-Gucy2e treated mice exhibited sig-
niﬁcantly reduced escape latencies (the amount of time required
to escape water bath via a platform demarcated with a ﬂag)
relative to untreated controls. Importantly, behavior of treated
mice was not signiﬁcantly different from age-matched WT con-
trols. Notably, these results were obtained in 1 year old GCDKO
mice treated 11 months prior, highlighting that retGC1 supple-
mentation confers useful cone-mediated vision to mammalian
models of LCA1 over the long term. This is signiﬁcant as
humans rely heavily on their cone-mediated vision for activ-
ities of daily living. It is also interesting to note that while
cone-mediated ERG improvements in both GC1KO and GCDKO
controls ranged between 45 and 65% that of WT controls, cone-
mediated behavior was restored to “normal” in AAV-treated mice
supporting previous work showing that behavior is a more sen-
sitive indicator of therapy (Williams and Jacobs, 2007). This
was also shown to be the case in LV-retGC1 treated GUCY1∗B
chickens whose modest ERG responses corresponded, albeit
transiently, to robust visually guided behavior (Williams et al.,
2006).
HOW DO ROD PHOTORECEPTORS RESPOND TO
TREATMENT?
Prior to the most comprehensive clinical characterization of LCA1
patients published to date (Jacobson et al., 2013), multiple reports
had described that both rod/cone function and rod/cone structure
were compromised (Perrault et al., 1999a,b; Milam et al., 2003;
Porto et al., 2003; den Hollander et al., 2008; Chung and Traboulsi,
2009; Jacobson et al., 2013). It was clear that, despite the presence
of retGC2 in these cells (Lowe et al., 1995), rod photoreceptors of
LCA1 patients are negatively impacted by retGC1 deﬁciency. Thus,
the speciﬁc effects of post-natal gene replacement therapy on this
photoreceptor subclass needed to be analyzed. Prior studies were
conducted in a model that lacks rod degeneration and retains vari-
able levels of rod function throughout its life, the GC1KO mouse.
For these reasons, it was not possible to address whether gene
replacement would prevent degeneration of rods or deﬁnitively
restore their function, respectively. Signiﬁcant improvements in
rod-mediated ERGs were only obtained when vector was deliv-
ered prior to natural eye opening (P10; Mihelec et al., 2011), but it
is difﬁcult to ascertain whether these gains are meaningful because
GC1KOmice exhibit normal rod-mediated visual behavior. It was-
not until generation of the GCDKO mouse that it became possible
to ask these questions (Baehr et al., 2007).
Deletion of both retGC1 and retGC2 in the GCDKO mouse
(Baehr et al., 2007) renders both cones and rods functionally silent
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(ERGs are unrecordable) and degenerative (Baehr et al., 2007).
Several cone proteins (GCAP1, GCAP2, cone opsins, cone trans-
ducin, cone PDE, GRK1) are downregulated/mislocalized) and
PDE6 is absent from rods (Baehr et al., 2007) in this model. By
2 months of age, overall outer segment length is reduced to 30–
50% of normal (Baehr et al., 2007). Appreciable thinning of the
outer nuclear layer (ONL) is apparent by ∼3.5 months of age and
by 6 months, only 3–4 photoreceptor nuclei remain (Boye et al.,
2013).
For its success in the studies described above, AAV8(Y733)-
hGRK1 was chosen to subretinally deliver Gucy2e to cohorts of
GCDKO mice of various age groups (P18, P21–P25, P37–P49,
and P108). ERG revealed that, like the cone results described
above, rod function was also stably restored to ∼40% of nor-
mal (at least 1 year post-treatment; Boye et al., 2013). Morris
Water Maze testing revealed that these functional gains trans-
lated to useful rod-mediated vision, with AAV-retGC1- treated
GCDKO mice performing the task at speeds that did not differ
signiﬁcantly from age-matched WT controls (Boye et al., 2013).
As in the treated GC1KO mice, WT-like behavior was achievable
in GCDKO mice that exhibited only partial ERG recovery. Optical
coherence tomography (OCT) was used to monitor the rate of
photoreceptor degeneration (predominantly rods) in treated vs.
untreated mice. By 7–12 months post-treatment, there was sig-
niﬁcant structural preservation in all treated GCDKOs, barring
those treated at the latest time point (P108), although retinas in
these mice still exhibited greater preservation than controls (Boye
et al., 2013). Importantly, the rate of photoreceptor cell loss in
GCDKO mice treated as late as P49 was no different from that
of age-matched WT controls. GCAP1 and GCAP2 were expressed
at WT-like levels at 1 year post-injection and cone opsins were
present only in treated cones (Boye et al., 2013). Taken together,
this study showed for the ﬁrst time that, along with the rescue
effects seenon cones,AAV-mediated retGC1expression can restore
rod photoreceptor function and rod-mediated visual behavior and
preserve rod structure over the long term in an animal model of
LCA1.
WHAT IS THE FUNCTIONAL EFFICIENCY OF AAV- DELIVERED
retGC1 ENZYME?
In considering clinical application of a gene therapy, an important
question becomes “how efﬁcient is the vector-derived, recombi-
nant gene product relative to the native protein?” The ability to
assess this in vivo provides a powerful bioassay which can be
used to establish dose-response relationships and equivalencies
for batches of clinical vectors. Guanylate cyclase activity assays
are performed on dark-adapted retinas to determine how much
cGMP is produced by retGCs in the presence of a [α-32P]GTP
substrate (Olshevskaya et al., 2004; Peshenko et al., 2011). This
assay doesnot discriminate between the activity of retGC1 and
retGC2. Therefore, isolating the functional efﬁciency of exoge-
nous retGC1 requires delivery to photoreceptors that lack both
endogenous retGC1 and retGC2, such as those in the GCDKO
mouse. Boye et al. (2013) compared retGC activity in retinas of
GCDKOmice thatwere treated subretinally betweenP30–P60with
AAV8(Y733F)-hGRK1-Gucy2e, relative to untreated GCDKO or
WT controls and those that received a serotype-matched control
vector expressing GFP. Maximal retGC activity in AAV-Gucy2e
treated retinas was ∼63% of normal. The known contribu-
tion to total cyclase activity by retGC2 in this assay is between
20 and 28% (Peshenko et al., 2011). In addition, the area of
retGC1 expression in treated retinas is known to be restricted
to the subretinal injection bleb (Timmers et al., 2001; Cideciyan
et al., 2008). “Good” subretinal injections typically result in ∼80–
90% detachment meaning not all photoreceptors expressed the
enzyme. Taking these two factors into account, the level of
retGC1 activity suggested its near-complete restoration in the area
exposed to vector. When the maximal activity of AAV-retGC1
was normalized to that seen in WT retinas, it was determined
that the calcium sensitivity of the exogenous and endogenous
enzymes were identical (Boye et al., 2013). Moving forward, this
assay may be used to evaluate the relative potency of clinical
vectors.
WHAT ARE THE CONSEQUENCES OF retGC1 DEFICIENCY ON
HUMAN ROD AND CONE PHOTORECEPTOR STRUCTURE AND
FUNCTION?
While there is general consensus that LCA1 is associated with
severely attenuated or ablated ERG (Perrault et al., 1999b, 2000;
Hanein et al., 2004; Yzer et al., 2006; den Hollander et al., 2008),
reports on the extent of photoreceptor degeneration associated
with this form of LCA have been conﬂicting (Milam et al., 2003;
Porto et al., 2003; Simonelli et al., 2007; Pasadhika et al., 2010).
Themost thorough clinical characterization of LCA1performed to
date focused on a cohort of patients ranging in age from 6 months
to 37 years with different mutations in GUCY2D and has provided
new insight on the effects of retGC1 deﬁciency on retinal structure
and function (Jacobson et al., 2013).
Similar to previous reports Simonelli et al. (2007), Pasadhika
et al. (2010), Jacobson et al. (2013) found that LCA1 patients
retained normal retinal laminar architecture aside from foveal
cone outer segment abnormalities and, in some cases, foveal cone
loss. Within rod-dominant retina, ONL thickness and outer seg-
ment lengths were normal in all patients (Jacobson et al., 2013).
Unlike previous reports, Jacobson et al. (2013) found that LCA1
patients can retain substantial rod function. Full ﬁeld sensitiv-
ity testing (FST) revealed all patients effectively used their rods
to detect blue stimuli, albeit at reduced sensitivities. These psy-
chophysical ﬁndings were supported by ERG, pupillometry and
mobility testing, all of which revealed variable levels of retained
rod function that did not correlate with the patient’s age (Jacob-
son et al., 2013). In contrast, the majority of patients lacked cone
sensitivity (FST) which correlated to severely reduced visual acuity
and a lack of color perception. FST, microperimetry and mobil-
ity tests revealed a small subset had detectable, but reduced cone
function with central ﬁxation and some color perception. None of
the patients had recordable cone-mediated ERGs (Jacobson et al.,
2013).
To better understand these differential cone phenotypes, Jacob-
son et al. (2013) investigated the activity of patient-speciﬁc retGC1
mutants in vitro. Their activity was assayed by transfecting cDNA
for each form, along with GCAPs in HEK293 cells under appro-
priate ionic conditions and quantifying the amount of cGMP
produced relative to that achieved with wild type retGC1. Of the
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patient-speciﬁc mutants tested, some exhibited reduced catalytic
activity (4–5 fold lower than WT) while others demonstrated no
loss of function (Jacobson et al., 2013). Not surprisingly, those
mutants that retained biochemical activity were expressed by
LCA1 patients with measurable cone function. It is expected that
those with normal activity in vitro may exhibit defective folding,
expression or impaired trafﬁcking to photoreceptor outer seg-
ments in situ. Investigations are currently underway to understand
the fate of these mutants in vivo via AAV-mediated expression in
GCDKO mice. retGC1 mutants that exhibited no activity in vitro
corresponded to patients with profound loss of cone function
(Jacobson et al., 2013).
WHAT FORM MIGHT A CLINICAL TRIAL FOR GUCY2D-LCA1
TAKE?
A few important choices must be made prior to clinical applica-
tion of a gene replacement therapy for LCA1. These include the
injection route and location, AAV serotype and promoter, and
therapeutic endpoints. Route and location of injection should be
dictated by the calculated risk(s)/beneﬁt. The structural integrity
of the patient’s retina and locus of existing vision must be con-
sidered. Evidence suggests GUCY2D-LCA1 is unlike any form
of LCA studied in detail to date (Jacobson et al., 1998, 2003,
2005, 2007a,b, 2009b, 2011; Cideciyan et al., 2007). Their hall-
mark retinal preservation suggests that LCA1patientsmay be good
candidates for subretinal injection of AAV-GUCY2D (Simonelli
et al., 2007; Pasadhika et al., 2010; Jacobson et al., 2013). Because
retGC1 deﬁciency leads to profound visual impairment, stemming
primarily from cones, the central retina should be the treatment
target. In the small subset of patients that exhibit foveal cone losses,
para- or peri-foveal areas may be targeted in the hopes that, like
some RPE65-LCA2 patients, they will develop an eccentric locus
of ﬁxation (Cideciyan et al., 2009).
AAV5andAAV8-based vectorswereused in the aforementioned
studies for developing a treatment for LCA1. These vectors have
proven utility for photoreceptor-targeted therapy following sub-
retinal injection in multiple mouse and dog models of inherited
retinal disease (Min et al., 2005; Alexander et al., 2007; Boye et al.,
2010, 2013; Gorbatyuk et al., 2010; Komaromy et al., 2010; Mao
et al., 2011; Pang et al., 2011, 2012; Yao et al., 2011; Beltran et al.,
2012; Petit et al., 2012; Lheriteau et al., 2014). Because AAV trans-
duction proﬁles and the activity of promoters can vary across
species, the ﬁnal decision should be dictated by the serotype and
promoter combination’s behavior in a species most closely related
to man, non-human primate (NHP). In LCA1, photoreceptors
of the central retina are the treatment target. Therefore, serotype
and promoter combinations that effectively transduce cone pho-
toreceptors in NHP are required. Transduction of both AAV5
and AAV8 vectors have recently been described in subretinally
injected NHP (Boye et al., 2012; Vandenberghe et al., 2013). Only
partial cone transduction was achieved following subretinal deliv-
ery of elevated doses of AAV8 containing the ubiquitous CMV
promoter driving GFP (1011 vg delivered; Vandenberghe et al.,
2011, 2013). At a lower dose (1010 vg delivered), AAV8-CMV-
GFP failed to transduce foveal, parafoveal or perifoveal cones
(Vandenberghe et al., 2011). In contrast, foveal, parafoveal, per-
ifoveal and peripheral cones of NHP (as well as rods) were all
effectively transduced following subretinal delivery of an AAV5
vector containing the photoreceptor-speciﬁc hGRK1 promoter
(1010 vg delivered; Boye et al., 2012). This mirrors earlier ﬁnd-
ings in rodent that hGRK1 has exclusive activity in cones and
rods (Khani et al., 2007; Tan et al., 2009; Boye et al., 2010, 2011;
Pawlyk et al., 2010; Sun et al., 2010). Taken together, these results
support the use of subretinally delivered AAV5-hGRK1-GUCY2D
in a clinical setting.
Because LCA1 patients exhibit profound cone-mediated visual
impairment and variable levels of rod-mediated vision, typi-
cal measures of vision must be supplemented with assays that
are more suited to this severe disease. Most patients have
nystagmus, making full ﬁeld ERG recordings difﬁcult. Addi-
tionally, because many LCA1 patients have unrecordable ERGs
to begin with, it would be impossible to measure any nega-
tive treatment-associated changes with this assay. Tests which
control for nystagmus such as microperimetry can be used to
assess cone-mediated central vision (Cideciyan et al., 2012). Tests
such as chromatic FST which was used in the most recent clin-
ical characterization (Jacobson et al., 2013) and in the clinical
trial for RPE65-LCA2 (Jacobson et al., 2012) could be used to
measure localized improvements in rod function. The limits of
variability for this assay have already been deﬁned in patients
with various retinal degenerations, including LCA (Roman et al.,
2005; Roman et al., 2007; Jacobson et al., 2009a). OCT should
be performed to monitor the safety of injections performed
under the fovea or para/peri- fovea, with emphasis placed on
the former given the slow return of cone outer segment struc-
ture observed in LCA2 patients treated subfoveally (Jacobson et al.,
2012). The potential effects of amblyopia must also be consid-
ered. It is possible that AAV-mediated expression of wild type
retGC1 in cones of LCA1 patients will reset their signaling cas-
cade allowing for electrochemical signals to propagate through
the retina, but that these signals will not be effectively relayed
to the brain. Magnetic resonance imaging studies could be used
to conﬁrm the integrity of higher order visual processing path-
ways prior to treatment. Fully understanding how the brain of an
LCA1 patient will accommodate GUCY2D gene replacement and
whether this will differ depending the patient’s mutation and/or
level of cone preservation will only be accomplished through a
clinical trial.
CONCLUSION
Information gleaned from proof of concept experiments in multi-
ple animal models of retGC1 deﬁciency have laid the groundwork
for development of an AAV-based treatment for GUCY2D-
LCA1 (Haire et al., 2006; Williams et al., 2006; Boye et al., 2010,
2011; Mihelec et al., 2011). Thorough clinical characterization of
patients has provided new insights into the pathophysiology of this
severe early onset inherited retinal disease, pointing to the central
retina as the target for treatment and highlighting the impor-
tance of selecting appropriate outcome measures by which to
score therapeutic efﬁcacy in a clinical trial (Jacobson et al., 2013).
Studies in NHP have revealed an optimal AAV serotype (AAV5)
and promoter (hGRK1) combination for delivery of therapeutic
transgene to all cone subclasses and rods (Boye et al., 2012). The
majority of genes (13/19) known to account for some form of
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LCA, including GUCY2D, encode photoreceptor speciﬁc proteins
(den Hollander et al., 2008; Wang et al., 2009; Estrada-Cuzcano
et al., 2011; Sergouniotis et al., 2011; Abu-Saﬁeh et al., 2013). In
fact, inherited retinal diseases as a whole are caused primarily
by defects in proteins expressed by photoreceptors (Wright et al.,
2010), a cell type yet to be targeted by AAV in a clinical setting.
Thus, developing a treatment for GUCY2D-LCA1 will serve as
a framework for other photoreceptor-targeted gene replacement
strategies.
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